List of Excipients in Branded Drug BALSALAZIDE DISODIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Oceanside Pharmaceuticals	BALSALAZIDE DISODIUM	balsalazide disodium	68682-750	MAGNESIUM STEARATE
Oceanside Pharmaceuticals	BALSALAZIDE DISODIUM	balsalazide disodium	68682-750	SILICON DIOXIDE

Generic Drugs Containing BALSALAZIDE DISODIUM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	balsalazide disodium	0054-0079	AMMONIA
Hikma Pharmaceuticals USA Inc	balsalazide disodium	0054-0079	BUTYL ALCOHOL
Hikma Pharmaceuticals USA Inc	balsalazide disodium	0054-0079	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in BALSALAZIDE DISODIUM?

# Of NDCs	Excipient
1	ALCOHOL
11	AMMONIA
6	BUTYL ALCOHOL

Balsalazide Disodium Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Balsalazide disodium is an off-patent, colon-targeted 5-aminosalicylic acid prodrug used for mildly to moderately active ulcerative colitis. Its commercial value is concentrated in formulation execution: preserving the prodrug through the upper gastrointestinal tract, enabling bacterial cleavage in the colon, reducing capsule burden, and improving pediatric administration. The leading opportunities are generic supply, lower-burden oral dosage forms, sprinkle-compatible capsules, and differentiated colon-release products.

What is the formulation and mechanism of balsalazide disodium?

Balsalazide disodium is an azo-bonded prodrug that releases mesalamine in the colon after bacterial cleavage. The formulation does not need to deliver large systemic exposure. It must instead transport intact balsalazide through the stomach and small intestine and permit conversion after reaching the colon.

The reference product, Colazal, is supplied as 750 mg capsules. The labeled adult dose is 6.75 g per day, equivalent to nine 750 mg capsules, administered as three capsules three times daily. Pediatric patients five to 17 years old receive weight-based dosing, which can also create a significant capsule burden.[1]

Core technical requirements

A commercial formulation should satisfy four performance requirements:

1. Maintain chemical stability during manufacturing and storage.
2. Limit premature release or degradation in gastric and small-intestinal conditions.
3. Preserve delivery to the colon.
4. Support bacterial conversion to mesalamine after colonic arrival.

Balsalazide has a distinct advantage over conventional mesalamine products because the active moiety is chemically linked to a carrier group until it reaches the bacterial environment of the colon. The excipient system must protect that mechanism rather than create a competing release profile.

What excipients are used in balsalazide disodium capsules?

The Colazal label identifies a conventional hard-gelatin capsule platform containing excipients such as microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate, with capsule-shell components including gelatin and colorants.[1] Generic products can use different excipients if they meet quality, bioequivalence, stability, and regulatory requirements.

Functional excipient roles

Formulation function	Common excipient category	Relevance to balsalazide
Bulking and powder structure	Microcrystalline cellulose, mannitol, dibasic calcium phosphate	Supports capsule fill weight and content uniformity
Flow improvement	Colloidal silicon dioxide	Reduces powder cohesion and improves encapsulation
Lubrication	Magnesium stearate, stearic acid, sodium stearyl fumarate	Controls tooling and capsule-machine performance
Binding	Povidone, pregelatinized starch, hydroxypropyl cellulose	Useful if granulation is required
Moisture control	Low-moisture diluents, desiccant packaging	Important for long-term assay and impurity control
Taste and administration	Gelatin or vegetarian capsule shells	Supports swallowing and potential sprinkle presentations
Modified release	Methacrylate polymers, cellulose derivatives, ethylcellulose	Relevant to tablet, pellet, or multiparticulate platforms
Processing protection	Antioxidant or chelating systems where justified	Must be supported by impurity and stability data

The most commercially relevant excipient decisions are not the colorant or lubricant. They are the carrier system, moisture-control strategy, release-control technology, and dosage-form architecture.

What excipient strategy best supports a generic balsalazide product?

The lowest-risk approach is a capsule formulation that closely follows the reference product's physical and performance characteristics. A conventional immediate-release capsule can be commercially attractive because balsalazide's colon targeting is primarily chemical and microbiological rather than dependent on a sophisticated enteric coating.

Strategy 1: Reference-like hard capsule

A reference-like product can use:

• Microcrystalline cellulose as the principal diluent.
• Colloidal silicon dioxide for flow.
• Magnesium stearate or another approved lubricant.
• A hard-gelatin capsule shell.
• Packaging with controlled moisture exposure.

This approach minimizes development complexity and can reduce the risk that excipients alter dissolution, powder handling, or assay uniformity.

The principal weakness is commercial sameness. A capsule-only product competes mainly on price, supply reliability, wholesaler access, and regulatory approval timing.

Strategy 2: Sprinkle-compatible capsule

The label for Colazal permits capsule contents to be opened and sprinkled on applesauce for pediatric administration, subject to the product instructions.[1] A generic product that preserves this administration option can compete on usability without changing the underlying active ingredient.

The excipient strategy should support:

• Low dust generation.
• Uniform powder distribution after capsule opening.
• Acceptable mouthfeel.
• Limited adhesion to food.
• Stability during brief contact with the vehicle.
• No requirement for crushing or extensive manipulation.

A capsule designed for sprinkling may have stronger commercial value than a nominally cheaper capsule if it improves pediatric adherence and pharmacy substitution acceptance.

Strategy 3: Lower-burden dosage form

The nine-capsule adult regimen creates an opportunity for larger-strength units, tablets, or multiparticulate products. A 1,125 mg or 1,500 mg unit could reduce daily pill count, but the feasibility depends on powder density, capsule size, swallowability, content uniformity, and regulatory bridging.

A higher-strength product would have to address:

• Large fill volume.
• Dose uniformity across units.
• Capsule-size limitations.
• Mechanical integrity.
• Patient ability to swallow the dosage form.
• Bioequivalence to the reference product or an approved regulatory pathway for the new strength.

A single 1,500 mg capsule could reduce the daily count from nine to five or six units, depending on the dosing schedule. The commercial value would be highest in adults with chronic maintenance needs and in patients who discontinue treatment because of pill burden.

What formulations are protected or differentiated by excipients?

The main differentiation opportunities are formulation platforms rather than basic excipient selection.

Enteric-coated tablets

An enteric-coated tablet could use an acid-resistant polymer such as a methacrylic acid copolymer or an alternative cellulose-based coating. The target would be delayed disintegration until passage through the stomach and proximal small intestine.

The technical risk is that an enteric coating may create a release profile that differs from the reference capsule. Balsalazide already depends on bacterial cleavage, so excessive delay could reduce colonic availability or change the site of conversion.

Multiparticulates and pellets

Pellets can improve dose flexibility and permit a more controlled distribution of drug throughout the colon. Possible architectures include:

• Drug-layered inert spheres.
• Matrix pellets.
• Polymer-coated granules.
• Capsule-filled multiparticulates.
• Sprinkle-compatible coated particles.

Multiparticulates may provide better dispersion than a single tablet and could support pediatric dosing. Their disadvantages are higher manufacturing complexity, more demanding coating control, and a greater risk of bioequivalence questions.

Osmotic or high-control delivery systems

Osmotic systems are technically possible but commercially less attractive. They add cost and manufacturing complexity without a clear need for a systemically absorbed drug whose key activity occurs after colonic bacterial conversion.

Taste-masked oral granules

Taste-masked granules could target pediatric and dysphagia populations. The system would need to prevent premature exposure of balsalazide while avoiding an unpleasant residue in the mouth. A polymer-coated granule in a sachet or capsule could support flexible dosing, but it would likely require a more complex regulatory and clinical justification than a capsule.

When does balsalazide disodium lose exclusivity?

Balsalazide disodium is generally treated as an off-patent small molecule. The original Colazal approval dates to 1997, and generic balsalazide products entered the U.S. market years ago. The commercial question is therefore not whether the original active-ingredient patent blocks entry. It is whether a new formulation creates separate intellectual-property value.

U.S. exclusivity and Orange Book status

Issue	Commercial assessment
Active ingredient	Off-patent small molecule
Reference product	Colazal, balsalazide disodium
FDA pathway	ANDA for therapeutically equivalent generic products
Regulatory exclusivity	Original exclusivity has expired
Orange Book relevance	Listed patents, if any, must be checked against the current FDA edition
Biosimilar pathway	Not applicable
Formulation opportunity	Possible only through a differentiated dosage form or delivery system
Primary barrier	Bioequivalence, manufacturing scale, and supply economics

For a launch decision, the FDA Orange Book remains the controlling source for current listed patents, exclusivity codes, and therapeutic-equivalence designations.[2] The legacy product does not present the same biologic patent risk associated with monoclonal antibodies or the same active-ingredient patent risk associated with newly approved small molecules.

Are Paragraph IV challenges relevant to balsalazide disodium?

Paragraph IV litigation is less central now than it was during the original generic entry period because the product is already genericized. A new ANDA applicant could still file a Paragraph IV certification if it identifies an unexpired Orange Book-listed patent covering the reference product or a relevant formulation.

The likely risk profile is:

• Low risk from the expired active-ingredient estate.
• Low-to-moderate risk from any remaining formulation or method-of-use listing.
• Higher risk if a new product relies on a proprietary enteric coating, multiparticulate design, or pediatric delivery platform.
• Limited litigation value where the formulation is a straightforward reference-like capsule.

FDA approval and patent clearance remain separate matters. An ANDA can receive approval while patent litigation continues, subject to statutory stays and settlement terms.[3]

What patent estate could protect a new balsalazide formulation?

A new product would need claims directed to a specific technical feature rather than generic use of balsalazide disodium.

Potential claim categories

Composition claims

Claims could cover:

• A defined balsalazide-to-diluent ratio.
• A low-moisture formulation.
• A specific lubricant concentration.
• A controlled particle-size distribution.
• A specified impurity profile.
• A capsule fill with improved content uniformity.

Composition claims are most defensible when the formulation produces a measurable performance benefit, such as improved stability or reduced dissolution variability.

Dosage-form claims

Claims could cover:

• A coated tablet that resists gastric conditions.
• A multiparticulate capsule.
• A sprinkle formulation.
• A high-strength capsule.
• A sachet containing taste-masked granules.
• A dosage form with defined release thresholds in sequential dissolution media.

Method-of-use claims

Possible claims could focus on:

• Pediatric ulcerative colitis treatment.
• Reduced capsule burden.
• Administration with a specified food vehicle.
• A dosing regimen designed around a higher-strength unit.
• Use in patients who cannot swallow conventional capsules.

Method-of-use protection is weaker where the method merely repeats the approved ulcerative-colitis indication. Stronger claims require a defined patient population, measurable adherence benefit, or a distinct administration method.

Manufacturing claims

Manufacturing IP could cover:

• Low-shear blending.
• Granulation conditions.
• Moisture-controlled encapsulation.
• Particle engineering.
• Coating processes.
• In-process controls that reduce content uniformity failures.

Manufacturing claims can create practical barriers even when composition claims are narrow, particularly if the process improves yield or reduces batch failure.

How strong is the patent estate for balsalazide disodium?

The legacy patent estate is weak as a barrier to conventional generic entry. The stronger opportunity is a new, narrow estate around delivery and manufacturing.

Asset type	Likely strength	Commercial value
Original active-ingredient protection	Low because expired	Minimal blocking value
Conventional capsule composition	Low to moderate	Protects a narrow product configuration
Sprinkle-compatible product	Moderate	Supports pediatric differentiation
High-strength dosage form	Moderate	Can reduce pill burden
Coated multiparticulate system	Moderate to strong if technically distinct	May support premium pricing
Method-of-use claims	Variable	Depends on clinical specificity
Manufacturing process	Moderate	Can protect yield and consistency
Broad excipient claims	Low	Vulnerable to design-around

The most durable strategy combines composition, process, dissolution-performance, and use claims. A single patent covering a list of ordinary excipients is unlikely to create a durable competitive barrier.

What FDA regulatory pathway applies to balsalazide disodium?

A conventional generic capsule generally proceeds through an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. The applicant must also satisfy current good manufacturing practice, stability, labeling, container-closure, and quality requirements.[4]

Key regulatory workstreams

Pharmaceutical equivalence

The product should match the reference product in:

• Active ingredient.
• Strength.
• Dosage form.
• Route of administration.
• Labeling, subject to permitted generic changes.

Bioequivalence

For a locally acting or minimally absorbed product, systemic pharmacokinetics may not fully represent therapeutic equivalence. The sponsor must follow the FDA's current product-specific requirements and justify the analytical and clinical approach.

Dissolution and release testing

Testing should examine:

• Acid-stage behavior.
• Buffer-stage transition.
• Release under physiologically relevant conditions.
• Batch-to-batch reproducibility.
• The effect of lubricant concentration and compression force.
• Stability-related changes in dissolution.

Inactive Ingredient Database

Each proposed excipient and route-specific level should be evaluated against the FDA Inactive Ingredient Database. A new excipient, new route, or higher level can increase regulatory burden.[5]

What commercial opportunities exist for balsalazide disodium?

1. Reliable generic supply

The simplest opportunity is a compliant, dependable generic. Balsalazide is a chronic-use product with a defined physician and pharmacy base. Supply interruptions, contract-manufacturing failures, or limited distributor coverage can create openings for a new supplier.

The product's relatively modest complexity makes it suitable for:

• Contract development and manufacturing.
• Regional generic launches.
• Private-label pharmacy distribution.
• Hospital and integrated-delivery-system contracts.
• Dual-source supply agreements.

2. Pediatric administration

The approved age range beginning at five years creates a clear formulation segment. A sprinkle-compatible capsule, taste-masked granule, or flexible-dose sachet could improve administration without changing the active ingredient.

The principal constraints are pediatric palatability, dose flexibility, stability after opening, and the need to preserve colon delivery.

3. Pill-burden reduction

Adult dosing is a commercially visible weakness. Higher-strength capsules, tablets, or multiparticulates could reduce daily unit count.

A lower-burden product would compete on adherence and convenience rather than only on acquisition cost. It may also have greater value in specialty pharmacy channels, where patient support and persistence are part of the product proposition.

4. Formulary and payer positioning

Balsalazide competes with mesalamine products, sulfasalazine, and other ulcerative-colitis therapies. It can be positioned as an oral, colon-targeted alternative with a different prodrug mechanism.

Pricing power is limited because:

• Multiple mesalamine products are available.
• Generic substitution is established.
• Biologic and small-molecule advanced therapies dominate severe disease.
• Payers can place older oral therapies into lower-cost tiers.

A differentiated dosage form must therefore demonstrate a practical benefit, not only a new excipient list.

How does balsalazide compare with competing ulcerative-colitis drugs?

Product class	Colon targeting	Generic pressure	Main commercial advantage	Main weakness
Balsalazide disodium	Bacterial cleavage of azo prodrug	High	Colon-directed mesalamine release	High capsule burden
Mesalamine delayed-release tablets	Enteric and pH-dependent delivery	High	Broad product availability	Product-specific release behavior
Mesalamine extended-release capsules	Extended release	High	Different dosing schedules	More complex formulation
Sulfasalazine	Azo prodrug cleavage	High	Low cost and long history	Tolerability and adverse effects
Biologics	Systemic immune modulation	Variable	Higher efficacy in moderate-to-severe disease	Cost, administration, immunogenicity
Oral targeted small molecules	Systemic immune modulation	Lower	Potent advanced therapy	Safety monitoring and cost

Balsalazide is most commercially competitive in mild-to-moderate ulcerative colitis, especially where oral therapy and generic pricing remain priorities.

What manufacturing and IP barriers affect launch timing?

The active ingredient is not the primary barrier. The practical barriers are:

• Reliable high-dose API sourcing.
• Control of powder flow and capsule fill uniformity.
• Moisture-related stability.
• Scale-up of blending and encapsulation.
• Consistent dissolution performance.
• Packaging that protects assay and impurity limits.
• FDA review of bioequivalence and product quality.
• Channel access after approval.

A differentiated product faces added barriers from coating uniformity, multiparticulate size distribution, dose segregation, and process validation. These barriers can be valuable if they are difficult to replicate, but they also increase development cost and delay.

What litigation, licensing, and settlement issues affect the product?

Balsalazide does not have the active litigation profile of recently approved specialty drugs. The original innovator's commercial position has been overtaken by generic competition, and the key legal issues for a new entrant are likely to involve formulation patents, manufacturing know-how, trademarks, and supply agreements.

Potential licensing targets include:

• Coating technologies.
• Multiparticulate manufacturing platforms.
• Taste-masking systems.
• Pediatric dosage-form technology.
• High-density capsule-filling processes.
• Low-moisture packaging systems.

A licensing deal is most defensible where the technology reduces development time or solves a demonstrated manufacturing problem. Licensing ordinary excipients or standard hard-capsule technology would offer limited strategic value.

Key Takeaways

• Balsalazide disodium is an off-patent colon-targeted small molecule with established generic competition.
• The reference product uses a conventional capsule platform, making a reference-like generic the lowest-risk development path.
• The best excipient opportunities involve stability, powder handling, sprinkle administration, and modified-release delivery.
• Pediatric formulations and lower-pill-burden products provide the clearest commercial differentiation.
• A new patent estate would likely depend on multiparticulates, high-strength units, taste-masked granules, release performance, or manufacturing processes.
• Paragraph IV risk is secondary to bioequivalence, manufacturing reliability, and commercial pricing.
• Balsalazide has no biosimilar pathway because it is a chemically synthesized small molecule.
• The most practical launch opportunity is a reliable generic supported by pediatric usability or reduced capsule burden.

FAQs

Can balsalazide disodium be formulated as a tablet instead of a capsule?

Yes. A tablet is technically feasible, but the sponsor must establish pharmaceutical equivalence or an acceptable regulatory pathway and demonstrate comparable performance. Tablet size, compression, coating, disintegration, and dissolution become central development variables.

Is an enteric coating required for balsalazide disodium?

Not necessarily. The prodrug's colon targeting depends on bacterial cleavage, and the reference product is a capsule. An enteric coating may be useful for a differentiated product but can create bioequivalence and release-profile risk.

Can balsalazide disodium be sold as a liquid?

A liquid or suspension is possible in principle, but chemical stability, dose uniformity, palatability, microbial control, and preservation would materially increase development complexity. A dry granule or sprinkle product is likely to be more practical.

Which excipient is most important for balsalazide capsule manufacture?

The principal excipient system is the combination of diluent, glidant, and lubricant. Microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate can influence powder flow, capsule-fill consistency, dissolution, and scale-up performance.

Does balsalazide disodium have biosimilar competition?

No. Biosimilars apply to biological products. Balsalazide disodium is a chemically synthesized small molecule and competes through generic drug pathways, primarily ANDAs in the United States.

References

1. U.S. Food and Drug Administration. (2017). Colazal (balsalazide disodium) capsules prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA): Paragraph IV certifications.
4. U.S. Food and Drug Administration. (2014). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry.
5. U.S. Food and Drug Administration. (2024). Inactive ingredient database.